The US Food and Drug Administration has six weeks to decide whether to follow an advisory panel’s unanimous recommendation to approve the first OTC switch proposal for a naloxone product or to ask the sponsor to test labeling it didn’t reveal until the panel’s meeting.
The agency will weigh approving Emergent BioSolutions, Inc.’s supplemental new drug application for OTC sales of its Narcan (naloxone/4...







